ClinVar Miner

Submissions for variant NM_001308120.2(TOGARAM1):c.3361A>G (p.Thr1121Ala)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard RCV003984292 SCV004800965 uncertain significance Brown syndrome 2024-03-13 criteria provided, single submitter curation The heterozygous p.Thr1121Ala variant in TOGARAM1 was identified by our study, in the compound heterozygous state with a variant of uncertain significance (dbSNP ID: rs201399500), in monozygotic twins with Brown syndrome, via a collaborative study between the Broad Institute's Center for Mendelian Genomics and the Engle lab (https://kirbyneuro.org/EngleLab/). These individuals also carried a variant of uncertain significance (dbSNP ID: rs201399500), however the phase of these variants are unknown at this time. We believe this is a possible phenotype expansion for TOGARAM1-related disorders. The p.Thr1121Ala variant in TOGARAM1 has not been previously reported in individuals with Joubert syndrome 37 but has been identified in 0.03% (4/15280) of Latino/Admixed American chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs200833388). Although this variant has been seen in the general population in a heterozygous state, its frequency is not high enough to rule out a pathogenic role. Computational prediction tools, including splice predictors, and conservation analyses suggest that this variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, the clinical significance of the p.Thr1121Ala variant is uncertain. ACMG/AMP Criteria applied: BP4 (Richards 2015).
Ambry Genetics RCV004369924 SCV004968690 uncertain significance not specified 2022-08-16 criteria provided, single submitter clinical testing The c.3361A>G (p.T1121A) alteration is located in exon 9 (coding exon 9) of the FAM179B gene. This alteration results from a A to G substitution at nucleotide position 3361, causing the threonine (T) at amino acid position 1121 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.